-
公开(公告)号：US20080160030A1
公开(公告)日：2008-07-03
申请号：US11883961
申请日：2006-02-09
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的蛋白质亚型的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US07888481B2
公开(公告)日：2011-02-15
申请号：US12367030
申请日：2009-02-06
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US08333965B2
公开(公告)日：2012-12-18
申请号：US13252335
申请日：2011-10-04
IPC分类号： A61K39/395 , A61K38/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（IFNα）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1，K的生物活性的抗体， 4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20090214565A1
公开(公告)日：2009-08-27
申请号：US12367030
申请日：2009-02-06
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H 2，I，J 1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20140154239A1
公开(公告)日：2014-06-05
申请号：US13705289
申请日：2012-12-05
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US08080638B2
公开(公告)日：2011-12-20
申请号：US11883961
申请日：2006-02-09
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括M×A启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20080112924A1
公开(公告)日：2008-05-15
申请号：US11931317
申请日：2007-10-31
CPC分类号： A61K35/28 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , A61K2039/6043
摘要： The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
-
公开(公告)号：US20130064855A1
公开(公告)日：2013-03-14
申请号：US13611976
申请日：2012-09-12
申请人： Anna Karolina Palucka , Jacques F. Banchereau , Florentina Marches , Chun Yu , SangKon Oh , Te-Chia Wu
发明人： Anna Karolina Palucka , Jacques F. Banchereau , Florentina Marches , Chun Yu , SangKon Oh , Te-Chia Wu
IPC分类号： A61K31/716 , A61K39/00 , A61P35/00
CPC分类号： A61K39/0011 , A61K31/716 , A61K35/15 , A61K2039/5154
摘要： Compositions and methods for the treatment of cancer disclosed herein. The method of the present invention comprises administration of compositions comprising β-glucan, a natural ligand for dectin-1, to block OX40L expression on tumor associated mDCs by blocking STAT6 phosphorylation. The β-glucan-treated mDCs secrete higher levels of IL-12p70 and do not expand TNFα and IL-13-producing CD4+ T cells, further resulting in inhibition of Th2 responses. Thus, compositions disclosed herein reprogram the function of mDCs in breast tumor microenvironment and turn tumor promoting Th2-type chronic inflammation into Th1-type acute inflammation that are able to reject tumors. The present invention finds particular uses for the intratumoral administration of the composition thereby directly binding to and directing a Th1-type acute inflammation.
摘要翻译： 本文公开的用于治疗癌症的组合物和方法。 本发明的方法包括施用包含葡聚糖的组合物，其是dectin-1的天然配体，通过阻断STAT6磷酸化阻断肿瘤相关mDC上的OX40L表达。 葡聚糖处理的mDC分泌更高水平的IL-12p70，不扩大TNFα和IL-13产生的CD4 + T细胞，进一步导致Th2应答的抑制。 因此，本文公开的组合物重新编码mDC在乳腺肿瘤微环境中的功能，并将肿瘤促进Th2型慢性炎症转化为能够排斥肿瘤的Th1型急性炎症。 本发明特别用于肿瘤内施用组合物，从而直接结合并导向Th1型急性炎症。
-
9.发明申请公开(公告)号：US20120020960A1
公开(公告)日：2012-01-26
申请号：US13189244
申请日：2011-07-22
IPC分类号： A61K39/395 , A61P35/00 , A61P29/00 , A61K38/16 , C07K16/24
CPC分类号： A61K45/06 , A61K39/395 , C07K16/24
摘要： Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13+TNFα+IL-10negCD4+ T cells (Th2 cells). Thus, TSLP, and/or down-stream pathways, represent novel potential therapeutic targets against human breast cancer.
摘要翻译： 本文提供了人类乳腺癌免疫治疗方法的组合物和方法。 胸腺基质淋巴细胞生成素（TSLP）和/或OX40L的任何拮抗剂通过阻断暴露于乳腺癌的DCs上调OX40L从而抑制其产生炎症性IL-13 +TNFα+ IL- 10negCD4 + T细胞（Th2细胞）。 因此，TSLP和/或下游途径代表了针对人类乳腺癌的新型潜在治疗靶点。
-
公开(公告)号：US09862927B2
公开(公告)日：2018-01-09
申请号：US13011798
申请日：2011-01-21
IPC分类号： A61K39/21 , C12N5/0784 , C07K14/005 , A61K39/12 , A61K39/00
CPC分类号： C12N5/0639 , A61K39/12 , A61K39/21 , A61K2039/5154 , A61K2039/545 , A61K2039/6018 , C07K14/005 , C12N2501/052 , C12N2501/22 , C12N2501/24 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.026 秒)